ClinicalTrials.gg

Program

Dendritic Cell

Its studies are mostly in Diabetic Nephropathies · Glioblastoma · Prostatic Neoplasms, led by 2 companies.

Furthest: phase 3, since Aug 6, 20023 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Northwest Biotherapeutics20 open or runningphase 3since Aug 6, 2002Aug 6, 2002none ahead
PT. JES Kasih Nusantara Sejahterah11 open or runningphase 2since Feb 22, 2025Feb 22, 2025none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2002First study: phase 3 study in Prostatic NeoplasmsNew to Northwest BiotherapeuticsNorthwest Biotherapeutics · NCT00043212 · United States
  2. Sep 17, 2002Phase 3 study in GlioblastomaNorthwest Biotherapeutics · NCT00045968 · 348 enrolled · United States, Canada, Germany and more
  3. Feb 22, 2025PT. JES Kasih Nusantara Sejahterah's first study: phase 2 study in Diabetic NephropathiesNew to PT. JES Kasih Nusantara SejahterahPT. JES Kasih Nusantara Sejahterah · NCT06866158 · 80 enrolled · Indonesia

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06866158Diabetic Nephropathies · Indonesia2Active, not recruitingPT. JES Kasih Nusantara SejahterahAug 5, 202480
NCT00045968Glioblastoma · United States, Canada, Germany and more3UNKNOWNNorthwest BiotherapeuticsNov 2022348
NCT00043212Prostatic Neoplasms · United States3WithdrawnNorthwest Biotherapeutics0

How it is read

Names in the registry

  • “Dendritic cell immunotherapy”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.